Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial

Background Limited options result in objective responses in patients with well-differentiated neuroendocrine tumors (WD-NET). We tested the efficacy of dual immune checkpoint blockade in patients with WD-NET. Methods We planned a phase II clinical trial in patients with WD-NET who progressed within the past 12 months to standard treatments. Patients received ipilimumab 1 mg/kg every 6 weeks and nivolumab 240 mg every 2 weeks for up to 2 years. The primary endpoint was objective response rate (ORR) by RECIST v1.1. Using Simon’s 2-stage design, the study planned to accrue 56 patients. This regimen would be considered promising if ORR >15%. Results Nine patients were enrolled (6 lung, 2 pancreatic, and 1 small bowel). The Mean age was 63.7 years. Four of eight evaluable patients achieved confirmed response (ORR 50%, 95% CI: 16–84). Five of nine patients experienced immune-related toxicity. The trial closed before completing Stage 1 enrollment (9 of 20 planned patients). No formal statistical conclusion could be applied given the incomplete accrual. We observed a higher CD3 infiltration in pre-treatment tumors of patients who had achieved radiological response as compared with those of nonresponders. Conclusions The combination of ipilimumab and nivolumab in patients with WD-NET results in an observed ORR of 50% in this small clinical trial. These results are hypothesis-generating given the small sample size and premature trial closure. Clinical trial registration https://clinicaltrials.gov/study/NCT03420521 , identifier NCT03420521

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-13
DOI
https://doi.org/10.3389/fimmu.2026.1824034
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial

Benjamin Philip Levy, Julie Renee Brahmer, Robert A. Anders, Ana De Jesus‐Acosta et al.
2 links
Frontiers in Immunology
Cancer Immunotherapy and Biomarkers
article

Dual immune checkpoint blockade in advanced well-differentiated neuroendocrine tumors, a phase II clinical trial

Benjamin Philip Levy, Julie Renee Brahmer, Robert A. Anders, Ana De Jesus‐Acosta, Susan Combs Scott, Elizabeth M. Jaffee, Suqi Ke, Kristen Ashley Marrone, Patrick M. Forde, Christine L. Hann, Qingfeng Zhu, Chen Hu, Valsamo Anagnostou, Peter Bela Illei
article en

Abstract

Background Limited options result in objective responses in patients with well-differentiated neuroendocrine tumors (WD-NET). We tested the efficacy of dual immune checkpoint blockade in patients with WD-NET. Methods We planned a phase II clinical trial in patients with WD-NET who progressed within the past 12 months to standard treatments. Patients received ipilimumab 1 mg/kg every 6 weeks and nivolumab 240 mg every 2 weeks for up to 2 years. The primary endpoint was objective response rate (ORR) by RECIST v1.1. Using Simon’s 2-stage design, the study planned to accrue 56 patients. This regimen would be considered promising if ORR >15%. Results Nine patients were enrolled (6 lung, 2 pancreatic, and 1 small bowel). The Mean age was 63.7 years. Four of eight evaluable patients achieved confirmed response (ORR 50%, 95% CI: 16–84). Five of nine patients experienced immune-related toxicity. The trial closed before completing Stage 1 enrollment (9 of 20 planned patients). No formal statistical conclusion could be applied given the incomplete accrual. We observed a higher CD3 infiltration in pre-treatment tumors of patients who had achieved radiological response as compared with those of nonresponders. Conclusions The combination of ipilimumab and nivolumab in patients with WD-NET results in an observed ORR of 50% in this small clinical trial. These results are hypothesis-generating given the small sample size and premature trial closure. Clinical trial registration https://clinicaltrials.gov/study/NCT03420521 , identifier NCT03420521

Frontiers in ImmunologyVol. 17
Johns Hopkins University (US), Johns Hopkins Medicine (US), Sidney Kimmel Comprehensive Cancer Center (US)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon